Home
Live Updates
Regel Therapeutics details its proprietary T3 platform and development pipeline on its newly launched website, expands its Board of Directors and announces its Scientific Advisory Board. : comparemela.com
Regel Therapeutics details its proprietary T3 platform and development pipeline on its newly launched website, expands its Board of Directors and announces its Scientific Advisory Board.
/PRNewswire/ -- Regel Therapeutics, a next generation gene therapy company utilizing proprietary technology to develop clinical products modulating gene...
Related Keywords
Berkeley ,
California ,
United States ,
Cambridge ,
Cambridgeshire ,
United Kingdom ,
San Francisco ,
Wendy Chung ,
Orrin Devinsky ,
Steve Ruchefsky ,
Andrew Schiermeier ,
Nadav Ahituv ,
Kevin Bender ,
Gord Fishell ,
University Of California ,
Broad Institute ,
Department Of Neurology ,
Harvard Medical School ,
Epilepsy Center ,
Therapeutic Technology ,
Institute Member Of The Broad ,
Regel Co ,
Institute For Human Genetics ,
Therapeutic Sciences ,
Regel Therapeutics Inc ,
Clinical Genetics At Columbia University ,
Scientific Advisory Board ,
Regel Co Founder Orrin Devinsky ,
Scientific Advisory ,
Targeted Therapeutic Technology ,
Cougar Biotechnology ,
Regel President ,
Avencell Therapeutics ,
Founder Orrin Devinsky ,
Kennedy Family Professor ,
Clinical Genetics ,
Columbia University ,
Human Genetics ,
Institute Member ,
Associate Professor ,
Computer Amp Electronics ,
Health Care Amp Hospitals ,
Medical Pharmaceuticals ,
Biotechnology ,
Pharmaceuticals ,
Personnel Announcements ,
New Products Amp Services ,
comparemela.com © 2020. All Rights Reserved.